Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $39.89 Average Target Price from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report) has received a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $39.89.

A number of research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Truist Financial boosted their price objective on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Wells Fargo & Company cut shares of Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 price target on the stock. in a research report on Tuesday, December 19th. JPMorgan Chase & Co. boosted their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th.

Check Out Our Latest Report on Kymera Therapeutics

Insider Activity

In other news, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the transaction, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bruce Booth sold 71,764 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the sale, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 3,934 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $41.86, for a total transaction of $164,677.24. Following the sale, the chief financial officer now owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 487,346 shares of company stock valued at $19,999,112. Insiders own 16.67% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently bought and sold shares of KYMR. Amundi bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $49,000. Point72 Hong Kong Ltd bought a new position in shares of Kymera Therapeutics during the first quarter valued at about $53,000. Advisors Asset Management Inc. bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $58,000. Royal Bank of Canada lifted its position in shares of Kymera Therapeutics by 30.0% during the second quarter. Royal Bank of Canada now owns 2,773 shares of the company’s stock valued at $64,000 after purchasing an additional 640 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Kymera Therapeutics by 65.4% during the second quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company’s stock valued at $67,000 after purchasing an additional 1,146 shares in the last quarter.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $40.20 on Friday. The firm has a 50-day simple moving average of $38.17 and a 200 day simple moving average of $25.98. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31. The stock has a market cap of $2.46 billion, a PE ratio of -15.95 and a beta of 2.30.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. The firm had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The company’s revenue for the quarter was up 197.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.60) earnings per share. Research analysts forecast that Kymera Therapeutics will post -3.16 earnings per share for the current fiscal year.

About Kymera Therapeutics

(Get Free Report

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

See Also

Analyst Recommendations for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.